These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
559 related articles for article (PubMed ID: 21907221)
41. Changes in neurotrophic signaling pathways in brain areas of the chronic mild stress rat model of depression as a signature of ketamine fast antidepressant response/non-response. Derosa S; Misztak P; Mingardi J; Mazzini G; Müller HK; Musazzi L Prog Neuropsychopharmacol Biol Psychiatry; 2024 Jan; 128():110871. PubMed ID: 37793481 [TBL] [Abstract][Full Text] [Related]
42. Crosstalk Between Inflammation and Glutamate System in Depression: Signaling Pathway and Molecular Biomarkers for Ketamine's Antidepressant Effect. Cui W; Ning Y; Hong W; Wang J; Liu Z; Li MD Mol Neurobiol; 2019 May; 56(5):3484-3500. PubMed ID: 30140973 [TBL] [Abstract][Full Text] [Related]
43. Rapid antidepressant effects: moving right along. Martinowich K; Jimenez DV; Zarate CA; Manji HK Mol Psychiatry; 2013 Aug; 18(8):856-63. PubMed ID: 23689537 [TBL] [Abstract][Full Text] [Related]
44. Role of Serotonergic System in the Antidepressant Actions of mGlu2/3 Receptor Antagonists: Similarity to Ketamine. Chaki S; Fukumoto K Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30871246 [TBL] [Abstract][Full Text] [Related]
45. [Resolvins as novel targets for rapid-acting antidepressants]. Deyama S Nihon Yakurigaku Zasshi; 2020; 155(6):381-385. PubMed ID: 33132254 [TBL] [Abstract][Full Text] [Related]
46. Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression. Zhang JC; Yao W; Dong C; Yang C; Ren Q; Ma M; Han M; Hashimoto K Psychopharmacology (Berl); 2015 Dec; 232(23):4325-35. PubMed ID: 26337614 [TBL] [Abstract][Full Text] [Related]
47. The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL/6J mice. Pałucha-Poniewiera A; Podkowa K; Rafało-Ulińska A Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110239. PubMed ID: 33400944 [TBL] [Abstract][Full Text] [Related]
48. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan. Lauterbach EC Med Hypotheses; 2012 Jun; 78(6):693-702. PubMed ID: 22401777 [TBL] [Abstract][Full Text] [Related]
49. The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits. Witkin JM; Monn JA; Schoepp DD; Li X; Overshiner C; Mitchell SN; Carter G; Johnson B; Rasmussen K; Rorick-Kehn LM J Pharmacol Exp Ther; 2016 Jul; 358(1):71-82. PubMed ID: 27189960 [TBL] [Abstract][Full Text] [Related]
50. Ketamine as a novel antidepressant: from synapse to behavior. Murrough JW Clin Pharmacol Ther; 2012 Feb; 91(2):303-9. PubMed ID: 22205190 [TBL] [Abstract][Full Text] [Related]
51. The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Monteggia LM; Gideons E; Kavalali ET Biol Psychiatry; 2013 Jun; 73(12):1199-203. PubMed ID: 23062356 [TBL] [Abstract][Full Text] [Related]
52. Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: Direct inhibition and disinhibition. Miller OH; Moran JT; Hall BJ Neuropharmacology; 2016 Jan; 100():17-26. PubMed ID: 26211972 [TBL] [Abstract][Full Text] [Related]
53. The mechanistic basis for the rapid antidepressant-like effects of ketamine: From neural circuits to molecular pathways. Ren L Prog Neuropsychopharmacol Biol Psychiatry; 2024 Feb; 129():110910. PubMed ID: 38061484 [TBL] [Abstract][Full Text] [Related]